Drug
Resiquimod clinical trials
Also written R848.
Keep track of what changes. Save the resiquimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2004 (4)
| Year | Studies |
|---|---|
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2017 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 7
Graceway Pharmaceuticals, LLC (6) · Mayo Clinic (2) · University of British Columbia (2) · Galderma R&D (1) · Abramson Cancer Center at Penn Medicine (1) · Spirig Pharma Ltd. (1) · Akhilesh Jha (1) · Cambridge University Hospitals NHS Foundation Trust (1)
Often tested with
Tested in the same studies.
Resiquimod Gel CD11301 (1) · Gag:267-274 Peptide Vaccine (1)
Studies
Open first, then newest update. How each study uses resiquimod is read from its arms, and is right about nine times in ten.
Testing it · 15
- Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)RecruitingNot applicableAkhilesh JhaNCT06488118Written as R848
- Nasal Immune Challenge StudyRecruitingNot applicableCambridge University Hospitals NHS Foundation TrustNCT06021002Written as R848
- A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)CompletedPhase 2Galderma R&DNCT03292406Written as CD11301 0.03%
- Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)CompletedPhase 1/2Abramson Cancer Center at Penn MedicineNCT01676831Written as Topical resiquimod 0.06%
- Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By SurgeryCompletedEarly Phase 1Mayo ClinicNCT01748747Written as resiquimod
- Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis LesionsCompletedPhase 2Spirig Pharma Ltd.NCT01583816Written as Resiquimod 0.03%
- Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by SurgeryCompletedEarly Phase 1Mayo ClinicNCT00470379Written as resiquimod
- Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) AgonistsCompletedPhase 1University of British ColumbiaNCT01737580Written as resiquimod
- Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune ModulatorCompletedPhase 1/2University of British ColumbiaNCT00175435Written as Resiquimod gel
- An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric SubjectsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00116662Written as Resiquimod
- Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in AdultsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00114920Written as Resiquimod
- Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in AdultsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00115141Written as Resiquimod
- Study With a Topical Gel to Treat Common Warts in AdultsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00117923Written as Resiquimod
- Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric SubjectsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00116675Written as Resiquimod
- Study With a Topical Gel to Treat Common Warts in AdultsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00117871Written as Resiquimod
Codes
What other systems call resiquimod · ClinicalTrials.gg INT004198
- MeSH (NLM) C402365resiquimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) V3DMU7PVXFRESIQUIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q426054resiquimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C63958ResiquimodOne source FDA
- DrugBank DB06530One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C402365 | resiquimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | V3DMU7PVXF | RESIQUIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q426054 | resiquimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C63958 | Resiquimod | One source FDA |
| DrugBank | DB06530 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.